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Dear Editor
We read with great interest the study by Anderson et al.
recently published in Critical Care [1]. The study assessed
whether soluble mediators (IL-8, sTNFR1, and Ang-2)
could be used as biomarkers to “enrich” subject populations
with higher mortality risk in subsequent clinical trials. The
authors addressed “immunocompetence” of patients using
clinical parameters (APACHE-II score and/or presence of
ARDS). They found that both IL-8 and sTNFR1 (but not
Ang-2) were suitable for identification of patients with
higher mortality risk and concluded that IL-8 and sTNFR1
can be used as “prognostic enrichment factors” in future
clinical sepsis studies.
Biomarker-based prognostic enrichment appears im-
portant to select sample populations with a greater like-
lihood of having improved clinical outcomes following a
given therapeutic intervention. Although sTNFR1 and
IL8 levels may be associated with higher mortality in
certain sepsis patients, however, selection of the correct
“enrichment markers” should be performed cautiously
and based on a solid underlying biological rationale. This
may, for example, be of particular importance in the
field of clinical sepsis trials testing immunomodulatory
interventions where assessment of the pleiotropic cyto-
kine IL-8 would likely introduce considerable bias and
should thus not be used to stratify respective patient
populations. Failure of an adequate peri-interventional
characterization may at least partly explain the failure of
a number of previous sepsis trials testing immunological
interventions (e.g., corticosteroids, strategies testing anti-
TNF or anti-LPS). In the study by Anderson et al.,
“immunocompetency” in sepsis patients was defined
using clinical criteria. However, it seems that immuno-
competency, i.e., (functional) immune phenotype, cannot
be assessed by predominantly clinical parameters and
should be based on comprehensive functional immune
markers (e.g., mHLA-DR expression [2–4]) in order to
identify individuals who would benefit most from a given
intervention.
We are well aware that the focus of the article was to
address the important question of whether biomarker-
based enrichment would lead to better stratification of
future trial cohorts.
While we appreciate the insights provided by Ander-
son et al., we believe that it will be crucial (and challen-
ging) to continue the quest for the “correct” enrichment
markers to succeed in the design of novel therapeutic in-
terventions, which may require more extensive reverse
translational research and personalized treatment ap-
proaches [5]. In the light of failure of a large number of
previous clinical sepsis trials, it seems apparent that bio-
marker enrichment using appropriate mediators is
needed and may open several avenues towards more
personalized treatment approaches in sepsis.
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